Navigation Links
Gro-International to Develop BioElectronics' OTC Brands in European and African Markets

FREDERICK, Md., Feb. 14, 2013 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of unique inexpensive, patented, anti-inflammatory pain reliever devices is pleased to announce that Gro-International, SA, Geneva, Switzerland market developers and brand management have added ActiPatch® Musculoskeletal Pain Therapy, Allay™ Menstrual Pain Therapy, and the Smart Insole™ Heel Pain Therapy products to their select group of retail products portfolio.  The Gro-International management team has a substantial history building successful brands, as well as developing and implementing marketing strategies.

The Gro-International team includes Gregor Forbes , Ivan Tsibulsky , and Paul Screawn .  Mr. Forbes has over 28 years of experience in Fast Moving Consumer Goods (FMCG) and over-the-counter pharmaceuticals including 25 years at Procter & Gamble where he was General Manager of Global Development markets, and as a non executive director of Swiss Precision Diagnostics.  Mr. Screawn is the former Commercial Director, Global Development Markets Central & Eastern Europe, Middle East and Africa at Procter & Gamble.

Gro-International has developed a network of experienced brand managers covering the nine major markets that recruit and manage distributors, sales agents, advertising and marketing to enhance local brand development. In addition to recruiting new distributors, Gro-International will assume management responsibility for BioElectronics' new and existing distributors in the United Kingdom, Denmark, Malta, Spain, Balkans, Bulgaria, Greece, Cyprus, Czech Republic, Nigeria, Morocco, and South Africa.

Paul Screawn commented, "We have done extensive market research, competitive evaluations, and product analysis on BioElectronics' pain products.  We are eager to move these products to the next stage and fully develop this unique market opportunity. The new devices, pricing, safety, and the market demand for an exceptional painkiller, provides a profound market opportunity."

Andrew Whelan , CEO of BioElectronics stated, "This Agreement with Gro-International provides market coverage for in excess of 400,000 professional pharmacies which covers fifty percent (50%) of the medical device market. Most importantly, the principals of Gro-International have lived and worked in these markets and know the distributors and the cultures."

About BioElectronics Corporation
Drugs and heat patches provide temporary minimal pain relief by simply masking it but it always comes back.  ActiPatch provides 5x better pain relief and is 100% safer than over-the-counter drugs. BioElectronics Corporation is an award winning medical device developer and manufacturer of advanced medical devices.  Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ menstrual cycle pain therapy, and RecoveryRx™ for surgical procedures and wound care.  The unique therapy delivery system, using patented technology, provides a cost-effective in-home option to reduce soft tissue pain and inflammation, and to accelerate healing. For more information, please see   

Paul Knopick

SOURCE BioElectronics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Device Developers - Network at BIOMEDevice Boston Next Week
2. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
3. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
6. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
7. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
8. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
9. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Kitov Pharma ... (TASE: KTOV), a biopharmaceutical company focused on the development ... clinical conditions, today announced the closing of its previously ... ( ADSs ), each representing 20 ordinary shares of ... ADSs. The ADSs and warrants were issued in a ...
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... today announced that Chief Executive Officer Antonius Schuh, Ph.D., ... 27 th Annual Piper Jaffray Healthcare Conference. ... the New York Palace Hotel in New ... 1:30 p.m. EST. Mr. Schuh will be available for ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... Lake, IL (PRWEB) , ... November 25, 2015 , ... ... to announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto and ... case Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
(Date:11/25/2015)... ... 2015 , ... Beddit® has launched a new Android app for ... features a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and ... created by a proprietary algorithm. Beddit analyzes the data to provide an easy to ...
(Date:11/25/2015)... , ... November 25, 2015 , ... In an ongoing ... Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its ... surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 at ...
Breaking Medicine News(10 mins):